Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 221-328-2 | CAS number: 3068-76-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute toxicity:
Oral (OECD 401), rat: LD50 = 704 mg/kg bw
Dermal (OECD 402), rat: LD50 > 2000 mg/kg bw
Inhalation: no study available
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 Feb 1994 - 15 Dec 1994
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- other: CDF(F-344)Crl:BR VAF/PLUS
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc., Portage, MI, USA
- Age at study initiation: young adult
- Weight at study initiation: 144-175 g
- Fasting: 18-20 h prior to dosing until 3-4 h after dosing
- Housing: individual housing in wire-mesh cages
- Diet: Purina Certified Rodent Chow #5002, ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21.5±1.5
- Humidity (%): 20-66
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- MAXIMUM DOSE VOLUME APPLIED: 1.92 mL/kg
- Doses:
- 500, 1000, 2000 mg/kg bw (0.48, 0.96, 1.92 mL/kg)
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The rats were observed 1, 3, and 4 h post-dose on day of appplication (day 0) and once daily thereafter. Body weights were obtained on the day before treatment, the day of treatment and on days 7 and 14.
- Necropsy of survivors performed: yes (major organ systems of the cranial, thoracic and abdominal cavities were examined for all animals) - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 809 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 590 - 1 109
- Key result
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 704 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 499 - 993
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 969 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- 831 - 1 130
- Mortality:
- 500 mg/kg bw: 1/5 males (day 2) and 0/5 females
1000 mg/kg bw: 4/5 males (day 1-3) and 3/5 females (day 2-3)
2000 mg/kg bw: 5/5 males (day 1) and 5/5 females (day 1-2) - Clinical signs:
- other: 500 mg/kg bw: Males: wet yellow urogenital staining (1/5) Females: hypoactivity (2/5), wet yellow urogenital staining (3/5) 1000 mg/kg bw: Males: hypoactivity (5/5), ataxia (4/5), ocular discharge (3/5), tremors (4/5), prostration (2/5), hypothermia (2/
- Gross pathology:
- Animals that were found dead:
Gastrointestinal abnormalities were observed for the majority of the rats that died during the study. Reddened kidneys and/or reddened/white renal cortico-medullary junctions were observed. Five rats had reddened or dark red adrenal glands. Hemorrhages in the thymus glands were noted. Other findings at a low incidence included an oedematous abdominal cavity and congenital accessory splenic tissue. Various external surface mattings were observed.
Animals sacrificed at end of study:
White areas in the kidneys (1/5 males, 500 mg/kg bw) and dark red lungs (1/5 females, 1000 mg/kg bw) - Interpretation of results:
- other: CLP/EU GHS criteria are met, Category 4 classification required according to Regulations (EC) No 1272/2008
Reference
Table 1: Body weights of the animals in the acute oral toxicity study.
Dose group [mg/kg bw] |
|
BW±SD [g] |
|
|
|
|
|
day -1 |
day 0 |
day 7 |
day 14 |
2000 |
male |
178±9 |
156±7 |
- |
- |
|
female |
159±3 |
145±2 |
- |
- |
1000 |
male |
187±2 |
171±3 |
206±0 |
220±0 |
|
female |
165±3 |
155±3 |
161±1 |
173±1 |
500 |
male |
173±5 |
152±4 |
179±23 |
210±15 |
|
female |
165±4 |
149±4 |
161±6 |
168±4 |
Table 2: Clinical signs of the male animals in the acute oral toxicity study.
Clinical findings (number out of 5 animals) |
Males |
|
|
|
500 mg/kg bw |
1000 mg/kg bw |
2000 mg/kg bw |
Found dead |
1 |
4 |
5 |
Hypoactive |
0 |
5 |
5 |
Clear ocular discharge |
0 |
3 |
5 |
Wet brown urogenital staining |
0 |
1 |
2 |
Labored respiration |
0 |
1 |
2 |
Body cool to touch |
0 |
2 |
1 |
Ataxia |
0 |
4 |
5 |
Prostrate |
0 |
2 |
2 |
White frothy salivation |
0 |
0 |
3 |
Dried brown urogenital staining |
0 |
0 |
1 |
Convulsions |
0 |
0 |
1 |
Tremors |
0 |
4 |
2 |
Wet yellow urogenital staining |
1 |
0 |
1 |
Dried red material around nose |
0 |
1 |
1 |
Dried red material around mouth |
0 |
2 |
1 |
Clear wet matting around mouth |
0 |
3 |
1 |
Table 3: Clinical signs of the female animals in the acute oral toxicity study.
Clinical findings (number out of 5 animals) |
Females |
|
|
|
500 mg/kg bw |
1000 mg/kg bw |
2000 mg/kg bw |
Found dead |
0 |
3 |
5 |
Hypoactive |
2 |
5 |
5 |
Clear ocular discharge |
0 |
4 |
5 |
Wet brown urogenital staining |
0 |
5 |
3 |
Labored respiration |
0 |
2 |
5 |
Body cool to touch |
0 |
3 |
5 |
Ataxia |
0 |
5 |
5 |
Prostrate |
0 |
3 |
5 |
White frothy salivation |
0 |
1 |
3 |
Dried brown urogenital staining |
0 |
4 |
4 |
Tremors |
0 |
1 |
0 |
Wet yellow urogenital staining |
3 |
4 |
0 |
Dried red material around nose |
0 |
5 |
0 |
Dried red material around mouth |
0 |
3 |
3 |
Clear wet matting around mouth |
0 |
1 |
0 |
Table 4: Necropsy findings of the male and female animals in the acute oral toxicity study.
Necropsy findings (number out of 5 animals) |
Males |
|
|
Females |
|
|
|
500 mg/kg bw |
1000 mg/kg bw |
2000 mg/kg bw |
500 mg/kg bw |
1000 mg/kg bw |
2000 mg/kg bw |
Adrenal Glands - reddened - dark red |
0 0 |
1 1 |
2 0 |
0 0 |
1 0 |
0 0 |
Intestine - dark red contents |
0 |
2 |
5 |
0 |
3 |
4 |
Kidneys - reddened cortico-medullary junction - reddened - white cortico-medullary junction |
0
0 0 |
0
2 1 |
2
3 0 |
0
0 0 |
1
0 0 |
2
2 0 |
Lungs - mottled |
0 |
0 |
4 |
0 |
0 |
1 |
Spleen - accessory |
0 |
1 |
0 |
0 |
0 |
0 |
Stomach - dark red area - dark red content |
0 0 |
1 2 |
1 0 |
0 0 |
1 3 |
3 0 |
Thymus gland - hemorrhagic |
0 |
1 |
0 |
0 |
0 |
3 |
External surface - yellow matting - red matting - brown matting - clear matting - green matting |
0 0 0 0 0 |
0 2 0 1 0 |
4 5 2 0 0 |
0 0 0 0 0 |
1 2 2 0 1 |
1 2 1 1 1 |
Abdominal cavity - oedematous |
0 |
0 |
0 |
0 |
0 |
0 |
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 704 mg/kg bw
- Quality of whole database:
- The available information comprises an adequate and reliable study (Klimisch score 1), and is thus sufficient to fulfil the standard information requirements set out in Annex VII, 8.6, of Regulation (EC) No 1907/2006.
Acute toxicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- other: Crl:CD BR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Breeding Laboratories, Inc., Portage, MI, USA
- Age at study initiation: young adult
- Weight at study initiation: 220-267 g
- Fasting: 18-20 h prior to dosing until 3-4 after dosing
- Housing: individual housing in mesh-bottom cages
- Diet: Purina Certified Rodent Chow #5002, ad libitum
- Water: tap water, ad libitum
- Acclimation period: at least 7 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.1±0.2
- Humidity (%): 39.1-44.0
- Photoperiod (hrs dark / hrs light): 12/12 - Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- TEST SITE
- % coverage: 14-18% of total body surface
- Type of wrap if used: gauze bandaging secured with non-irritating tape
REMOVAL OF TEST SUBSTANCE
- Washing (if done): application sites were wiped with disposable paper towels moistened with deionized water
- Time after start of exposure: 24 h
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): 2000 mg/kg bw, 1.92 mL/kg - Duration of exposure:
- 24 h
- Doses:
- 2000 mg/kg bw
- No. of animals per sex per dose:
- 5
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: The rats were observed 1, 3, and 4 h post-dose on day of appplication (day 0) and once daily (clinical observation) or twice daily (mortality) thereafter. Body weights were obtained on the day of treatment and on days 7 and 14.
- Necropsy of survivors performed: yes (major organ systems of the cranial, thoracic and abdominal cavities were examined for all animals)
- Dermal observations: application sites were examined for erythema, oedema and other dermal findings 30-60 minutes after bandage removal and daily thereafter for thirteen days. The rats were clipped to facilitate dermal observations on study days 7 and 14. - Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Remarks on result:
- other: No mortality was observed.
- Mortality:
- No mortality was observed.
- Clinical signs:
- other: Clinical findings were limited to dried red material around the eye(s) and/or nose for seven rats and wet and dried yellow urogenital staining for five rats. These findings are typically noted in association with the bandage/collar application procedures
- Gross pathology:
- Reddened seminal vesicles and multiple calculi in the kidneys, ureter(s) and urinary bladder were noted in one male at the terminal necropsy. These are common, spontaneous findings in rats of this age and strain and were unrelated to the test material. One female had scabbing on the application site. There were no other gross necropsy findings for all examined tissues.
- Other findings:
- - Other observations:
The test material induced very slight to severe erythema, very slight edema and eschar on one animal. Desquamation was present on six animals. There were no other dermal findings. With the exception of one male and female with severe erythema, slight edema, eschar and/or desquamation, all dermal irritation completely subsided by day 11 or earlier. Skin reactions were determined using the Draize scoring system. - Interpretation of results:
- other: CLP/EU GHS criteria are not met, no classification required according to Regulations (EC) No 1272/2008
Reference
Table 1: Body weights of the animals in the acute dermal toxicity study.
Dose group [mg/kg bw] |
|
BW±SD [g] |
|
|
|
|
day 0 |
day 7 |
day 14 |
2000 |
male |
262±4 |
304±12 |
343±23 |
2000 |
female |
225±4 |
225±5 |
235±6 |
Table 2: Dermal observations of the males in the acute dermal toxicity study.
Rat No. (males) |
1 |
2 |
3 |
4 |
|
5 |
|
|||
Observation time [day no] |
Erythema |
Edema |
Erythema |
Edema |
Erythema |
Edema |
Erythema |
Edema |
Erythema |
Edema |
1 |
0d |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0d |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
0d |
0 |
5 |
0d |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
0d |
0 |
6 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0d |
0 |
0 |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
8 |
0d |
0 |
0 |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
9 |
0d |
0 |
0 |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
10 |
0d |
0 |
0 |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
11 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
d: desquamation
Table 3: Dermal observations of the females in the acute dermal toxicity study.
Rat No. (females) |
1 |
2 |
3 |
4 |
|
5 |
|
|||
Observation time [day no] |
Erythema |
Edema |
Erythema |
Edema |
Erythema |
Edema |
Erythema |
Edema |
Erythema |
Edema |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
3 |
0 |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
4 |
0 |
0 |
0d |
0 |
0 |
0 |
0 |
0 |
0d |
0 |
5 |
0 |
0 |
1d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
0 |
0 |
1d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
7 |
0 |
0 |
2d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
8 |
0 |
0 |
2d |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
9 |
0 |
0 |
3d |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
10 |
0 |
0 |
3d |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
11 |
0 |
0 |
4de |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
12 |
0 |
0 |
4de |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
13 |
0 |
0 |
4de |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
14 |
0 |
0 |
4de |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
d: desquamation
e: eschar
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 2 000 mg/kg bw
- Quality of whole database:
- The available information comprises an adequate and reliable study (Klimisch score 1), and is thus sufficient to fulfil the standard information requirements set out in Annex VIII, 8.6, of Regulation (EC) No 1907/2006.
Additional information
A key study is available with N-[3 -(trimethoxysilyl)propyl]aniline (CAS 3068 -76 -6), which was conducted according to OECD 401 and in compliance with GLP (WIL, 1994). Five male and female Fischer rats were treated with 500, 1000, and 2000 mg/kg bw by oral gavage. The test substance was applied undiluted (0.48, 0.96, 1.92 mL/kg).
The rats were observed 1, 3, and 4 h post-dose on day of appplication (day 0) and once daily thereafter for clinical signs and mortality. Body weights were obtained on the day before treatment, the day of treatment and on days 7 and 14. Necropsy of survivors was performed and major organ systems of the cranial, thoracic and abdominal cavities were examined for all animals.
In the low dose group 1/5 males and 0/5 females were found dead. Treatment with 1000 mg/kg bw led to 4/5 dead males and 3/5 dead females within day 1 -3 and 2 -3, respectively. All animals were found dead after treatment with 2000 mg/kg bw on days 1 -2. There were no remarkable changes or differences observed in body weights. Clinical signs mainly observed in the 1000 and 2000 mg/kg bw dose groups included hypoactivity, ataxia, ocular discharge, tremors, prostration, hypothermia, labored respiration, wet/dried brown urogenital staining, salivation, dried red material around the nose/mouth. All surviving animals appeared normal by day 4 or earlier. Necropsy findings included gastrointestinal abnormalities for the majority of the rats that died during the study. Reddened kidneys and/or reddened/white renal cortico-medullary junctions were observed. Five rats had reddened or dark red adrenal glands. Hemorrhages in the thymus glands were noted. Other findings at a low incidence included an oedematous abdominal cavity and congenital accessory splenic tissue. Various external surface mattings were observed. In conclusion, a combined LD50 of 809 mg/kg bw was calculated. The LD50 for males and females were 704 and 969 mg/kg bw, respectively.
Supporting data are available from another acute oral toxicity study with N-[3 -(trimethoxysilyl)propyl]aniline (CAS 3068 -76 -6), which was conducted according to OECD 401 and in compliance with GLP (WIL, 1996). Crj: CD (SD) rats (5 per sex) were treated with 500, 980, 1921, 2689 (only females), and 3765 (only females) mg/kg bw test substance by oral gavage. The test substance was dosed in corn oil at a maximum dose of 5 mL/kg bw.
The rats were observed 1, 3, and 4 h post-dose on day of appplication (day 0) and twice daily thereafter for clinical signs and mortality. Body weights were obtained on the day before treatment, the day of treatment and on days 7 and 14. Necropsy of survivors was performed and major organ systems of the cranial, thoracic and abdominal cavities were examined for all animals.
In the low dose group no mortality was observed. Treatment with 980 and 1921 mg/kg bw led to 1/10 and 4/10 dead animals within day 2 -3, respectively. As only males were affected, two further groups of 5 females were dosed with 2689 and 3765 mg/kg bw and mortality was observed in 1/5 and 5/5 animals within 3 and 0-2 days, respectively.
Clinical findings were noted in all dose groups. Twenty-three rats had wet and/or dried yellow urogenital, ventral abdominal and/or ventral thoracic staining. Hypoactivity and tremor was noted in the two high dose groups. Various dried red material around the eye(s), mouth, forelimb(s) and/or nose and abnormal excretion (mucoid faeces, soft stool, decreased defecation and/or urination) were observed for nine animals each. Six rats (two high-dose groups) had labored respiration. Clear wet matting around the mouth and hypothermia (body cool to touch) were noted for four rats each. Two animals of the two high dose groups (females) showed hair loss on the ventral abdominal and/or thoracic area, clear ocular discharge and prostration. Lacrimation in the right eye was noted for a single female. There were no other clinical findings. With the exception of hair loss on the ventral abdominal and/or thoracic area(s) for two rats, all animals appeared normal by day 9 or earlier and throughout the remainder of the study. There were no remarkable changes or differences observed in body weights.
Necropsy findings included dark red or mottled lungs in three out of eleven rats that were found dead. Two animals each had gastrointestinal abnormalities (dark red area(s) in the stomach or dark red intestinal contents) and reddened adrenal glands. A single male had opacity in the right eye. Various external matting (red and/or brown matting around the eyes, nose, mouth, anogenital and/or urogenital area) were noted for six out of eleven animals that died during the study. There were no other gross necropsy findings for all other animals found dead. Internal findings noted at the terminal necropsy were limited to a dilated renal pelvis (right) for a single male. Two females had hair loss on the ventral abdominal area. There were no other gross necropsy findings for all other surviving animals.
In conclusion, LD50 for males and females were 1379 and 2843 mg/kg bw, respectively.
A key study is available with N-[3 -(trimethoxysilyl)propyl]aniline (CAS 3068 -76 -6) for the dermal route, which was conducted according to OECD 402 and in compliance with GLP (WIL, 1995). Five male and female Crl:CD BR rats were treated with the limit dose of 2000 mg/kg bw by semi-occlusive dermal application for 24 h. The test substance was applied undiluted (1.97 mL/kg) to the back of the animals covering 14-18% of the total body surface. The application sites were wiped with disposable paper towels moistened with deionized water after 24 h.
The rats were observed 1, 3, and 4 h post-dose on day of appplication (day 0) and once or twice daily thereafter for clinical signs and mortality, respectively. Body weights were obtained on the day of treatment and on days 7 and 14. Necropsy of survivors was performed and major organ systems of the cranial, thoracic and abdominal cavities were examined for all animals. The application sites were examined for erythema, oedema and other dermal findings 30-60 minutes after bandage removal and daily thereafter for thirteen days. The rats were clipped to facilitate dermal observations on study days 7 and 14.
No mortality was observed. Clinical findings were limited to dried red material around the eye(s) and/or nose for seven rats and wet and dried yellow urogenital staining for five rats. These findings are typically noted in association with the bandage/collar application procedures and were not a result of test material application. There were no other clinical findings. All animals appeared normal by day 3 or earlier and throughout the remainder of the study. Two females lost 1-3 % of body weight and one female had zero gain from day 0 to day 7. Slight losses or lower gains in body weight are common in animals which have been bandaged and collared for 24 hours. The two females which had losses recovered and surpassed their initial (day 0) weights by termination (day 14). There were no other remarkable changes or differences in body weights. Reddened seminal vesicles and multiple calculi in the kidneys, ureter(s) and urinary bladder were noted in one male at the terminal necropsy. These are common, spontaneous findings in rats of this age and strain and were unrelated to the test material. One female had scabbing on the application site. There were no other gross necropsy findings for all examined tissues. The test material induced very slight to severe erythema, very slight edema and eschar on one animal. Desquamation was present on six animals. There were no other dermal findings. With the exception of one male and female with severe erythema, slight edema, eschar and/or desquamation, all dermal irritation completely subsided by day 11 or earlier. Skin reactions were determined using the Draize scoring system.
In conclusion, a dermal LD50 of >2000 mg/kg bw was derived for male and female animals.
Justification for classification or non-classification
The available data on acute oral toxicity of the registered substance meet the criteria for classification as “Harmful if swallowed (H302)” according to Regulation (EC) 1272/2008.
The available data on acute dermal toxicity of the registered substance do not meet the criteria for classification according to Regulation (EC) 1272/2008 and according to Directive 67/548/EEC, and are therefore conclusive but not sufficient for classification.
No data are availabe for the inhalation route.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.